Jiage Qian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiage Qian has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Paniccia
Division of GI Surgical Oncology, UPMC Pancreatic Cancer Center, University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, USA
5 shared publications Sebastiaan Ceuppens
Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
4 shared publicationsAatur Singhi
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
3 shared publicationsAmer H. Zureikat
Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
3 shared publicationsKenneth K. Lee
Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
3 shared publicationsAmer Zureikat
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
2 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 279-286
Comparative outcomes analysis of Whipple procedure in dialysis-dependent patients: A propensity-matched study using NSQIP data
- 31 January 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 279-286
Open AccessComparative outcomes analysis of Whipple procedure in dialysis-dependent patients: A propensity-matched study using NSQIP data
- Open Access
- 8 September 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110438
Ideal outcomes in pancreatic neuroendocrine tumor vs. adenocarcinoma following resection: A nationwide study using ACS-NSQIP
- 8 September 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110438
Open AccessIdeal outcomes in pancreatic neuroendocrine tumor vs. adenocarcinoma following resection: A nationwide study using ACS-NSQIP
- Open Access
- 31 July 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (4) , 695-705
Optimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19‐9 Dynamics
Background: Many patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with modified FOLFIRINOX (mFOLFIRINOX) require dose reduction due to adverse effects. This study explores the optimal threshold for mFOLFIRINOX relative dose intensity (RDI) and characterizes RDI's correlation with CA 19‐9.Methods: A single‐institution retrospective analysis of 97 patients with PDAC treated with mFOLFIRINOX and pancreatectomy from 2017 to 2022. RDI was calculated by dividing the delivered dose intensity by the intended dose intensity over 6 months.Results: Median overall RDI was 73.8% (fluorouracil 75.5%, irinotecan 74.5%, oxaliplatin 70.6%). An RDI cutoff of ≥ 70% (n = 57) was associated with significantly improved overall survival (median OS: 62.6 vs. 43.7 months, p = 0.034). Compared to patients with < 70% RDI who did not achieve CA 19‐9 normalization, those with ≥ 70% RDI and normalization had significantly improved survival (HR: 0.27; 95% CI: 0.11–0.73). No significant benefit was observed with ≥ 70% RDI without CA 19‐9 normalization or < 70% RDI with normalization. In the multivariable model, RDI ≥ 70% remained independently associated with improved OS (HR = 0.37, 95% CI: 0.18–0.79) but not disease‐free survival (HR = 0.50, 95% CI: 0.24–1.03).Conclusion: Receiving ≥ 70% RDI of mFOLFIRINOX and CA 19‐9 normalization independently improves survival in resected PDAC. The greatest benefit is observed when both are achieved.
- 31 July 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (4) , 695-705
Open AccessOptimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19‐9 Dynamics
Background: Many patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with modified FOLFIRINOX (mFOLFIRINOX) require dose reduction due to adverse effects. This study explores the optimal threshold for mFOLFIRINOX relative dose intensity (RDI) and characterizes RDI's correlation with CA 19‐9.Methods: A single‐institution retrospective analysis of 97 patients with PDAC treated with mFOLFIRINOX and pancreatectomy from 2017 to 2022. RDI was calculated by dividing the delivered dose intensity by the intended dose intensity over 6 months.Results: Median overall RDI was 73.8% (fluorouracil 75.5%, irinotecan 74.5%, oxaliplatin 70.6%). An RDI cutoff of ≥ 70% (n = 57) was associated with significantly improved overall survival (median OS: 62.6 vs. 43.7 months, p = 0.034). Compared to patients with < 70% RDI who did not achieve CA 19‐9 normalization, those with ≥ 70% RDI and normalization had significantly improved survival (HR: 0.27; 95% CI: 0.11–0.73). No significant benefit was observed with ≥ 70% RDI without CA 19‐9 normalization or < 70% RDI with normalization. In the multivariable model, RDI ≥ 70% remained independently associated with improved OS (HR = 0.37, 95% CI: 0.18–0.79) but not disease‐free survival (HR = 0.50, 95% CI: 0.24–1.03).Conclusion: Receiving ≥ 70% RDI of mFOLFIRINOX and CA 19‐9 normalization independently improves survival in resected PDAC. The greatest benefit is observed when both are achieved.
- Open Access
- 29 May 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 311, 250-258
Comparative Study of Pancreatic Acinar Cell Carcinoma and Pancreatoblastoma: Insights From the National Cancer Database
- 29 May 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 311, 250-258
Open AccessComparative Study of Pancreatic Acinar Cell Carcinoma and Pancreatoblastoma: Insights From the National Cancer Database
- 27 August 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (4) , 394.e1-394.e10
Insights from preventability assessments across 42 state and city maternal mortality reviews in the United States
- 27 August 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (4) , 394.e1-394.e10
Insights from preventability assessments across 42 state and city maternal mortality reviews in the United States
- Open Access
- 11 May 2023
- Published by International Society of Global Health in Journal of Global Health Reports
- Vol. 7, e2023011
Data for local decision-making, not a mere reporting requirement: development of an index to measure facility-level use of HMIS data
Background: Well-functioning health management information systems (HMIS) enable decision-making at all health system levels. This study develops an index to measure the use of HMIS data at the facility level. Methods: We used two rounds of cross-sectional data collected from 305 health facilities in Ethiopia in 2019 (pre-COVID-19) and 2020 (post-COVID-19). We constructed a summative, 10-item index using exploratory factor analysis and 2019 index development data; and used Cronbach’s alpha to assess reliability. To examine content validity, we mapped items against a previously published conceptual framework and consulted Ethiopian experts. We then employed one-way ANOVA and t-tests comparing the mean index scores overall and by key facility characteristics between 2019 and 2020. Results: The 10-item index loaded on one factor (Cronbach’s alpha=0.74), and the index scores did not differ significantly by facility characteristics in 2019. The mean index score increased from 7.2 in 2019 to 7.9 in 2020 (PP <0.05). Conclusions: We propose a facility-level HMIS data use index and document an upward trend in HMIS data use in Ethiopia immediately after the COVID-19 pandemic was declared. Future research should further evaluate and refine the proposed index to support the measurement of HMIS data quality and utilization in Ethiopia and like settings.
- 11 May 2023
- Published by International Society of Global Health in Journal of Global Health Reports
- Vol. 7, e2023011
Open AccessData for local decision-making, not a mere reporting requirement: development of an index to measure facility-level use of HMIS data
Background: Well-functioning health management information systems (HMIS) enable decision-making at all health system levels. This study develops an index to measure the use of HMIS data at the facility level. Methods: We used two rounds of cross-sectional data collected from 305 health facilities in Ethiopia in 2019 (pre-COVID-19) and 2020 (post-COVID-19). We constructed a summative, 10-item index using exploratory factor analysis and 2019 index development data; and used Cronbach’s alpha to assess reliability. To examine content validity, we mapped items against a previously published conceptual framework and consulted Ethiopian experts. We then employed one-way ANOVA and t-tests comparing the mean index scores overall and by key facility characteristics between 2019 and 2020. Results: The 10-item index loaded on one factor (Cronbach’s alpha=0.74), and the index scores did not differ significantly by facility characteristics in 2019. The mean index score increased from 7.2 in 2019 to 7.9 in 2020 (PP <0.05). Conclusions: We propose a facility-level HMIS data use index and document an upward trend in HMIS data use in Ethiopia immediately after the COVID-19 pandemic was declared. Future research should further evaluate and refine the proposed index to support the measurement of HMIS data quality and utilization in Ethiopia and like settings.